| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net earnings | 2,418 | 2,230 | 1,289 | 4,309 |
| Depreciation | 559 | 367 | 181 | 558 |
| Amortization of intangible assets | 5,593 | 3,722 | 1,858 | 5,726 |
| Deferred income taxes | -107 | -300 | -28 | -682 |
| Change in fair value of contingent consideration liabilities | 5,089 | 4,313 | 1,518 | 3,492 |
| Payments of contingent consideration liabilities | 2,184 | 1,408 | 549 | 1,456 |
| Stock-based compensation | 798 | 589 | 410 | 747 |
| Acquired ipr&d and milestones | 3,751 | 1,071 | 248 | 1,183 |
| Non-cash litigation reserve adjustments, net of cash payments | -1,069 | -750 | -729 | 341 |
| Impairment of intangible assets (excluding goodwill) | 847 | - | - | 0 |
| Other, net | -6 | -96 | -17 | 75 |
| Accounts receivable | 1,652 | 1,496 | 1,479 | 180 |
| Inventories | 209 | 211 | 155 | 191 |
| Prepaid expenses and other assets | 169 | 257 | 628 | -461 |
| Accounts payable and other liabilities | 1,549 | -181 | -696 | -1,070 |
| Income tax assets and liabilities, net | -1,408 | -997 | 378 | -1,405 |
| Cash flows from operating activities | 13,812 | 6,788 | 1,635 | 11,758 |
| Payments to acquire businesses, net of cash acquired | 204 | 204 | 204 | 17,493 |
| Other acquisitions and investments, net of cash acquired | 4,076 | 1,274 | 334 | 1,232 |
| Acquisitions of property and equipment | 885 | 504 | 235 | 683 |
| Purchases of investment securities | 29 | 22 | 10 | 46 |
| Sales and maturities of investment securities | 42 | 39 | 32 | 516 |
| Other, net | 28 | -49 | -16 | 8 |
| Cash flows from investing activities | -5,180 | -1,916 | -735 | -18,946 |
| Net change in commercial paper borrowings with original maturities of three months or less | 999 | 1,549 | 1,593 | - |
| Proceeds from issuance of other short-term borrowings | 4,798 | 4,007 | 0 | 5,008 |
| Repayments of other short-term borrowings | 2,007 | 0 | 0 | 5,008 |
| Proceeds from issuance of long-term debt | 3,994 | 3,994 | 3,994 | 14,963 |
| Repayments of long-term debt and finance lease obligations | 6,789 | 6,780 | 3,026 | 3,851 |
| Debt issuance costs | 23 | 23 | 20 | 99 |
| Dividends paid | 8,746 | 5,835 | 2,925 | 8,273 |
| Purchases of treasury stock | 977 | 973 | 961 | 1,350 |
| Proceeds from the exercise of stock options | 124 | 61 | 56 | 204 |
| Payments of contingent consideration liabilities | - | - | - | 0 |
| Other, net | 69 | 32 | 31 | 56 |
| Cash flows from financing activities | -8,558 | -3,968 | -1,258 | 1,650 |
| Effect of exchange rate changes on cash and equivalents | 31 | 39 | 9 | -19 |
| Net change in cash and equivalents | 105 | 943 | -349 | -5,557 |
| Cash and cash equivalents at beginning of period | 5,524 | - | - | - |
| Cash and cash equivalents at end of period | 5,629 | - | - | - |
AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV)